

24<sup>th</sup> January, 2023

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

---

This is with respect to our earlier communication on September 28, 2022 regarding the USFDA inspection at our manufacturing facility at Indrad, Gujarat and issuance of Form 483 by USFDA with 3 observations.

We now wish to inform that the Company has received a communication from the USFDA determining the inspection classification as “Official Action Indicated” (OAI). This inspection classification will not have impact on existing supplies or revenues from this facility.

Torrent Pharma continues to cooperate with the USFDA and will undertake all necessary remedial steps to resolve these issues to the satisfaction of the regulator. Torrent Pharma remains committed to being cGMP compliant quality standards across all its facilities.

Please take the information on record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg. Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,

[www.torrentpharma.com](http://www.torrentpharma.com), email id: [investorservices@torrentpharma.com](mailto:investorservices@torrentpharma.com)